George Techiryan1, Brian R Weil1, Beth A Palka1, John M Canty1. 1. From the VA WNY Health Care System and the Departments of Medicine, Pharmacology and Toxicology, Physiology and Biophysics, and Biomedical Engineering, and the Clinical and Translational Research Center of the University at Buffalo, NY.
Abstract
RATIONALE: Metformin has been demonstrated to decrease infarct size (IS) and prevent postinfarction left ventricular (LV) remodeling in rodents when given intravenously at the time of reperfusion. It remains unclear whether similar cardioprotection can be achieved in a large animal model. OBJECTIVE: The objective of this study was to determine whether intravascular infusion of metformin at the time of reperfusion reduces myocardial IS in a porcine model of acute myocardial infarction. METHODS AND RESULTS: In a blinded and randomized preclinical study, closed-chest swine (n=20) were subjected to a 60-minute left anterior descending coronary artery occlusion to produce myocardial infarction. Contrast-enhanced computed tomography was performed during left anterior descending coronary artery occlusion to assess the ischemic area-at-risk. Animals were randomized to receive either metformin or vehicle as an initial intravenous bolus (5 mg/kg) 8 minutes before reperfusion, followed by a 15-minute left coronary artery infusion (1 mg/kg per minute) commencing with the onset of reperfusion. Echocardiography and computed tomographic imaging of LV function were performed 1 week later, at which time the heart was removed for postmortem pathological analysis of area-at-risk and IS (triphenyltetrazolium chloride). Baseline variables including hemodynamics and LV function were similar between groups. Peak circulating metformin concentrations of 374±35 µmol/L were achieved 15 minutes after reperfusion. There was no difference between the area-at-risk as a percent of LV mass by computed tomography (vehicle: 20.7%±1.1% versus metformin: 19.7%±1.3%; P=0.59) or postmortem pathology (22.4%±1.2% versus 20.2%±1.2%; P=0.21). IS relative to area-at-risk averaged 44.5%±5.0% in vehicle-treated versus 38.2%±6.8% in metformin-treated animals ( P=0.46). There was no difference in global function 7 days after myocardial infarction as assessed by echocardiography or computed tomographic ejection fraction (56.2%±2.6% versus 56.3%±2.4%; P=0.98). CONCLUSIONS: In contrast to rodent hearts, postconditioning with high-dose metformin administered immediately before reperfusion does not reduce IS or improve LV function 7 days after myocardial infarction in swine. These results reinforce the importance of rigorously testing therapies in large animal models to facilitate clinical translation of novel cardioprotective therapies.
RATIONALE: Metformin has been demonstrated to decrease infarct size (IS) and prevent postinfarction left ventricular (LV) remodeling in rodents when given intravenously at the time of reperfusion. It remains unclear whether similar cardioprotection can be achieved in a large animal model. OBJECTIVE: The objective of this study was to determine whether intravascular infusion of metformin at the time of reperfusion reduces myocardial IS in a porcine model of acute myocardial infarction. METHODS AND RESULTS: In a blinded and randomized preclinical study, closed-chest swine (n=20) were subjected to a 60-minute left anterior descending coronary artery occlusion to produce myocardial infarction. Contrast-enhanced computed tomography was performed during left anterior descending coronary artery occlusion to assess the ischemic area-at-risk. Animals were randomized to receive either metformin or vehicle as an initial intravenous bolus (5 mg/kg) 8 minutes before reperfusion, followed by a 15-minute left coronary artery infusion (1 mg/kg per minute) commencing with the onset of reperfusion. Echocardiography and computed tomographic imaging of LV function were performed 1 week later, at which time the heart was removed for postmortem pathological analysis of area-at-risk and IS (triphenyltetrazolium chloride). Baseline variables including hemodynamics and LV function were similar between groups. Peak circulating metformin concentrations of 374±35 µmol/L were achieved 15 minutes after reperfusion. There was no difference between the area-at-risk as a percent of LV mass by computed tomography (vehicle: 20.7%±1.1% versus metformin: 19.7%±1.3%; P=0.59) or postmortem pathology (22.4%±1.2% versus 20.2%±1.2%; P=0.21). IS relative to area-at-risk averaged 44.5%±5.0% in vehicle-treated versus 38.2%±6.8% in metformin-treated animals ( P=0.46). There was no difference in global function 7 days after myocardial infarction as assessed by echocardiography or computed tomographic ejection fraction (56.2%±2.6% versus 56.3%±2.4%; P=0.98). CONCLUSIONS: In contrast to rodent hearts, postconditioning with high-dose metformin administered immediately before reperfusion does not reduce IS or improve LV function 7 days after myocardial infarction in swine. These results reinforce the importance of rigorously testing therapies in large animal models to facilitate clinical translation of novel cardioprotective therapies.
Authors: Chris P H Lexis; Iwan C C van der Horst; Erik Lipsic; Wouter G Wieringa; Rudolf A de Boer; Ad F M van den Heuvel; Hindrik W van der Werf; Remco A J Schurer; Gabija Pundziute; Eng S Tan; Wybe Nieuwland; Hendrik M Willemsen; Bernard Dorhout; Barbara H W Molmans; Anouk N A van der Horst-Schrivers; Bruce H R Wolffenbuttel; Gert J ter Horst; Albert C van Rossum; Jan G P Tijssen; Hans L Hillege; Bart J G L de Smet; Pim van der Harst; Dirk J van Veldhuisen Journal: JAMA Date: 2014-04-16 Impact factor: 56.272
Authors: Steven P Jones; Xian-Liang Tang; Yiru Guo; Charles Steenbergen; David J Lefer; Rakesh C Kukreja; Maiying Kong; Qianhong Li; Shashi Bhushan; Xiaoping Zhu; Junjie Du; Yibing Nong; Heather L Stowers; Kazuhisa Kondo; Gregory N Hunt; Traci T Goodchild; Adam Orr; Carlos C Chang; Ramzi Ockaili; Fadi N Salloum; Roberto Bolli Journal: Circ Res Date: 2014-12-11 Impact factor: 17.367
Authors: Marta Paiva; Niels P Riksen; Sean M Davidson; Derek J Hausenloy; Pedro Monteiro; Lino Gonçalves; Luís Providência; Gerard A Rongen; Paul Smits; Mihaela M Mocanu; Derek M Yellon Journal: J Cardiovasc Pharmacol Date: 2009-05 Impact factor: 3.105
Authors: Nassrene Y Elmadhun; Ashraf A Sabe; Antonio D Lassaletta; Louis M Chu; Frank W Sellke Journal: J Surg Res Date: 2014-05-17 Impact factor: 2.192
Authors: Gen Suzuki; Brian R Weil; Rebeccah F Young; James A Fallavollita; John M Canty Journal: Am J Physiol Heart Circ Physiol Date: 2019-05-24 Impact factor: 4.733
Authors: Ahmed A Mohsin; Qun Chen; Nanhu Quan; Thomas Rousselle; Michael W Maceyka; Arun Samidurai; Jeremy Thompson; Ying Hu; Ji Li; Edward J Lesnefsky Journal: J Pharmacol Exp Ther Date: 2019-03-07 Impact factor: 4.030
Authors: Maaike Te Lintel Hekkert; Gary Newton; Dirk J Duncker; Michael D Schneider; Kathryn Chapman; Rehan Aqil; Robert Downham; Robert Yan; Daphne Merkus; Gavin Whitlock; Charlotte A L Lane; Darren Cawkill; Trevor Perrior Journal: Basic Res Cardiol Date: 2021-05-20 Impact factor: 17.165
Authors: Daniel I Bromage; Tom R Godec; Mar Pujades-Rodriguez; Arturo Gonzalez-Izquierdo; S Denaxas; Harry Hemingway; Derek M Yellon Journal: Cardiovasc Diabetol Date: 2019-12-09 Impact factor: 8.949
Authors: Thomas R Godec; Daniel I Bromage; Mar Pujades-Rodriguez; Antonio Cannatà; Arturo Gonzalez-Izquierdo; Spiros Denaxas; Harry Hemingway; Ajay M Shah; Derek M Yellon; Theresa A McDonagh Journal: ESC Heart Fail Date: 2022-03-23
Authors: Arezoo Momeni; Lisa Eagler; Chi Y Lo; Brian R Weil; John M Canty; Jennifer K Lang; Sriram Neelamegham Journal: Biomaterials Date: 2021-07-27 Impact factor: 15.304